Vitamin B-6 and colorectal cancer risk: a prospective population-based study using 3 distinct plasma markers of vitamin B-6 status

Björn Gylling, Robin Myte, Jörn Schneede, Göran Hallmans, Jenny Häggström, Ingegerd Johansson, Arve Ulvik, Per M Ueland, Bethany Van Guelpen, and Richard Palmqvist

Departments of 3Medical Biosciences, Pathology, 4Radiation Sciences, Oncology, 5Clinical Pharmacology, Pharmacology and Clinical Neurosciences, 6Biobank Research, Public Health and Clinical Medicine, 7Statistics, Umeå School of Business and Economics, and 8Odontology, Cariology, Umeå University, Umeå, Sweden; 9Bevital AS, Bergen, Norway; and 10Department of Clinical Science, University of Bergen and Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

ABSTRACT

Background: Higher plasma concentrations of the vitamin B-6 marker pyridoxal 5'-phosphate (PLP) have been associated with reduced colorectal cancer (CRC) risk. Inflammatory processes, including vitamin B-6 catabolism, could explain such findings.

Objective: We investigated 3 biomarkers of vitamin B-6 status in relation to CRC risk.

Design: This was a prospective case-control study of 613 CRC cases and 1190 matched controls nested within the Northern Sweden Health and Disease Study (n = 114,679). Participants were followed from 1985 to 2009, and the median follow-up from baseline to CRC diagnosis was 8.2 y. PLP, pyridoxal, pyridoxic acid (PA), 3-hydroxykynurenine, and xanthurenic acids (XAs) were measured in plasma with the use of liquid chromatography–tandem mass spectrometry. We calculated relative and absolute risks of CRC for PLP and the ratios 3-hydroxykynurenine:XA (HK:XA), an inverse marker of functional vitamin B-6 status, and PA:(PLP + pyridoxal) (PAr), a marker of inflammation and oxidative stress and an inverse marker of vitamin B-6 status.

Results: Plasma PLP concentrations were associated with a reduced CRC risk for the third compared with the first quartile and for PLP sufficiency compared with deficiency [OR: 0.60 (95% CI: 0.44, 0.81) and OR: 0.55 (95% CI: 0.37, 0.81), respectively]. HK:XA and PAr were both associated with increased CRC risk [OR: 1.48 (95% CI: 1.08, 2.02) and OR: 1.50 (95% CI: 1.10, 2.04), respectively] for the fourth compared with the first quartile. For HK:XA and PAr, the findings were mainly observed in study participants with <10.5 y of follow-up between sampling and diagnosis.

Conclusions: Vitamin B-6 deficiency as measured by plasma PLP is associated with a clear increase in CRC risk. Furthermore, our analyses of novel markers of functional vitamin B-6 status and vitamin B-6–associated oxidative stress and inflammation suggest a role in tumor progression rather than initiation. Am J Clin Nutr 2017;105:897–904.

Keywords: biomarkers, colorectal cancer, inflammation, metabolite ratios, vitamin B-6

INTRODUCTION

Pyridoxal 5'-phosphate (PLP) is the active coenzyme form of vitamin B-6 and the most commonly used biomarker of vitamin B-6 status in epidemiologic studies, including investigations of colorectal cancer (CRC) risk (1). PLP has been proposed to influence carcinogenesis through its role in angiogenesis, one-carbon metabolism, cell proliferation, and inflammation (2).

In prospective case-control studies, individuals with higher plasma concentrations of PLP had a 30–50% lower risk of CRC (1, 3–7). In contrast, cohort studies of vitamin B-6 intake and randomized controlled trials of vitamin B-6 supplementation have been inconclusive (1, 8). The results for PLP have been explained by residual confounding because of other factors related to a healthy lifestyle, such as lower smoking rates, higher physical activity, and higher intake of other micronutrients in individuals with higher PLP concentrations (1). Moreover, the inverse association between plasma PLP concentrations and CRC risk may not be an expression of anticancer properties of vitamin B-6 itself but rather a reflection of inflammatory activity, which affects both vitamin B-6 status and CRC risk (9).

Inflammation promotes CRC development (10, 11). The inflammatory biomarker C-reactive protein (CRP) is associated with low PLP status (12, 13) but also increased CRC risk (10, 14–16). Low plasma PLP is also observed in inflammatory bowel...
disease (17), a CRC risk factor (17, 18). Accordingly, inflammation is one of the main predictors of reduced circulating vitamin B-6 concentrations (19). These observations suggest that the discrepancy between studies on intake compared with plasma concentrations of vitamin B-6 may be partly explained by the reduction of PLP concentrations because of inflammatory activity in persons at an increased risk of CRC.

Two ratios of plasma metabolites have been proposed as more robust indicators of vitamin B-6 status. The 3-hydroxykynurenine: xanthurenic acid (XA) ratio (HK:XA) is based on the role of PLP in tryptophan catabolism via the PLP-dependent kynurenine pathway. HK:XA is the ratio of 2 downstream catabolites of tryptophan, 3-hydroxykynurenine and XA. It is an indicator of functional vitamin B-6 status (20, 21). Pyridoxic acid (PA):(PLP + pyridoxal) ratio (PAR) is the ratio of plasma concentrations of the vitamin B-6 catabolite 4-PA and the sum of the active forms PLP and pyridoxal, i.e., PAR = PA:(PLP + pyridoxal). It is a more robust biomarker of systemic inflammation than PLP and efficiently discriminates high inflammatory status measured by CRP and other inflammatory biomarkers (22). Both ratios are negatively correlated with PLP concentrations. A recent study found that PAR but not HK:XA was associated with overall cancer risk, mainly in lung and colorectal cancers (23).

We investigated circulating markers of vitamin B-6 status, including plasma PLP concentrations and the novel biomarkers PAR and HK:XA, in relation to CRC risk in a large, population-based, nested case-control study with a long follow-up time.

METHODS

Study participants

This was a nested case-control study within the Northern Sweden Health and Disease Study. Participants from 2 population-based cohorts were included: the Västerbotten Intervention Program (VIP) (78.2% of the study participants) and Mammography Screening Project (MSP) (21.8% of the study participants). These cohorts have been described in detail previously (24). In the VIP, established in 1985, residents of Västerbotten County were invited to participate in a health survey upon turning 30, 40, 50, and 60 y of age. The health survey consisted of a medical examination and laboratory tests, donation of a fasting blood sample for future research, and completion of an extensive participant-administered lifestyle questionnaire. As of 31 March 2009, the stop date for the case identification for this study, the VIP included 115,147 blood samples from 85,877 individuals (Supplemental Figure 1). The population-based nature of the VIP cohort is supported by comparisons of cancer incidence rates (25), and the selection bias has been found to be low (26). In the MSP, established in 1995 and continued in 2006, women residing in Västerbotten County aged ~50–70 y were invited to complete a lifestyle questionnaire and donate a blood sample for future research while attending mammography screening. The MSP included 54,401 blood samples from 28,802 women.

CRC case participants diagnosed between 17 October 1986 and 31 March 2009 were identified by linkage with the essentially complete Cancer Registry of Northern Sweden. All cases and tumor data were verified by a single pathologist who specialized in gastrointestinal pathology. Patient records were used to verify the tumor site. Exclusion criteria were previous cancer diagnosis other than nonmelanoma skin cancer, location of primary tumor outside the colorectum, insufficient volume of stored plasma sample available, prioritization to other studies, serious infectious disease, or no matching control available. Two control participants were randomly selected for each case matched by sex, age at and year of blood sampling and data collection, cohort, and fasting status. The exclusion criteria for the controls were the same as for the cases. In addition, the control patients were all alive and with no diagnosed cancer other than nonmelanoma skin cancer at the time of diagnosis of their index cases. After exclusions (81 cases and 41 controls), 613 cases and 1190 controls were included for data analyses (Supplemental Figure 1).

The study protocol and data handling procedures were approved by the Umeå University Research Ethics Committee. All participants gave written informed consent at the time of recruitment to the VIP or MSP cohort. All samples and data were deidentified.

Blood sampling and analysis

The blood samples for this study were collected in sample tubes containing EDTA that were separated into plasma, Buffy coat, and erythrocyte fractions. The samples were then divided and cryopreserved at −80°C at a central location. Samples were frozen within 1 h of collection either at −80°C or −20°C for ≤1 wk before being transferred to a −80°C freezer. Samples in the VIP were collected in the morning, and only 34 of 1409 study participants (2%) had fasted for <4 h and 295 (21%) had fasted for <8 h. In the MSP, blood samples were collected throughout the day, and 379 of 393 study participants (96%) had fasted for <4 h. All biochemical analyses were performed at Bevital AS in 2011. Plasma concentrations of riboflavin, creatinine, and vitamin B-12 species were measured with LC-MS methods (27). Folate and vitamin B-12 concentrations were determined with the use of a microbiological method with the use of Lactobacillus casei and L. leichmannii, respectively, adapted to a microtiter plate format and carried out by a robotic workstation (28, 29). Interassay CVs for the plasma analyses were 7.1 for PLP, 12.7 for PA, 6.3 for pyridoxal, 9.7 for 3-hydroxykynurenine, and 14.6 for XA (30). The investigators and laboratory staff were blinded to case and control status.

Statistical analyses

We used Mann-Whitney U tests, chi-square tests, or linear regressions to test for differences in variable distributions. Measures of RRs for CRC in relation to the vitamin B-6 biomarkers were calculated as ORs with the use of conditional logistic regression. The markers were analyzed in groups divided into quartiles. The cutoff values were based on the distribution of the controls or as standardized log-transformed continuous variables. The trend across quartiles was tested by modeling quartile variables as continuous variables (labeled 1–4). Plasma PLP was also analyzed as sufficient compared with deficient with a cutoff at 20 nmol/L. This concentration is the basis of the mean requirements in the United States (31, 32). Absolute risk estimates in the form of marginal risk differences between estimated risks in the quartile groups of vitamin B-6
markers were computed with the weighted maximum likelihood estimator (33). Cumulative incidence data from the whole study cohort and within groups defined by sampling year, age, sex, and cohort were used (34). The cumulative incidence of CRC in the study cohort was ~830 cases/100,000 individuals from 1987 to 2009.

To evaluate dose-response and potential nonlinear relations, we modeled continuous log-transformed vitamin B-6 markers in relation to CRC risk with the use of restricted cubic splines (with 5 knots at the 5th, 25th, 50th, 75th, and 95th percentiles of the vitamin B-6 marker distributions). Nonlinearity was tested with a Wald test that compared the model with spline terms to a linear model.

To adjust for potential confounders, several variables with a plausible link to both exposure and outcome were considered. These included the plasma B vitamins folate, riboflavin, and vitamin B-12 (continuous, log-transformed); estimated glomerular filtration rate calculated by the Cockcroft-Gault formula (based on plasma creatinine concentrations, age, sex, and body weight) (35); smoking status; BMI (in kg/m²); alcohol intake; dietary fiber intake; and recreational and occupational physical activity. In the conditional logistic regression models, 3 models were estimated for each vitamin B-6 marker. Model 1 represented an unadjusted model. Model 2 was adjusted for estimated glomerular filtration, smoking status, BMI, alcohol intake, and recreational and occupational physical activity. Model 3 was additionally adjusted for the plasma B vitamins folate, riboflavin (vitamin B-2), and cobalamin (vitamin B-12). For the risk differences, a crude estimate adjusted only for the matching (vitamin B-6 status), were both associated with an increased CRC risk for the fourth compared with the first quartile [OR: 1.48 (95% CI: 1.08, 2.02), Pr_trend = 0.02; OR per 1-SD increase: 1.14 (95% CI: 1.02, 1.28)]. The risk association for PAr was similar for the fourth compared with first quartile [OR: 1.50 (95% CI: 1.10, 2.04), Pr_trend = 0.01; OR per 1-SD increase: 1.18 (95% CI: 1.05, 1.31)]. The corresponding absolute risk differences were a decrease in incidence of 325 cases/100,000 individuals for the third compared with the first quartile of PLP (decrease of 45 cases/100,000 individuals per 1-SD increase) and an increase of 211 and 273 cases/100,000 individuals for the fourth compared with the first quartiles of HK:XA and PAr (increase of 68 and 131 cases/100,000 individuals per 1-SD increase), respectively. The inclusions of potential confounders did not markedly alter any risk estimates.

Dose-response relations of the vitamin B-6-markers in relation to CRC risk modeled with restricted cubic splines are presented in Figure 2. Although linearity could not be rejected for any marker in the spline regressions, the association for PLP had nonlinear tendencies manifested as a U-shaped association with a particularly high risk for low concentrations (Pr_nonlinearity = 0.05).

In Figure 3, we present ORs according to follow-up time between sampling and CRC diagnosis. The association for PLP seemed to be similar across follow-up times. Pr_trend was significantly linearly associated with CRC risk for HK:XA and PAr in the subgroups with <10.5 y of follow-up but not for the HK:XA and PAr subgroups with ≥10.5 y of follow-up. Similarly, a per 1-SD increase was significantly associated with increased CRC risk in the HK:XA and PAr subgroups with <10.5 y of follow-up but not in the subgroups with ≥10.5 y of follow-up. However, overall heterogeneity for the associations between all follow-up groups was only significant for HK:XA (Pr_heterogeneity = 0.02). We observed no clear differences in associations between site, stage, sex, or age, and no overall tests of heterogeneity were significant (Supplemental Tables 2–4). However, a 1-SD increase of PAr was significantly associated with left-sided CRC (Supplemental Table 2).

RESULTS

Baseline characteristics of cases and controls and tumor characteristics are presented in Table 1. The median age at diagnosis was 65.2 y (5th–95th percentile: 50.3–76.2 y). Baseline data for BMI, physical activity, and alcohol intake were comparable for cases and controls. There was a slightly higher frequency of ex-smokers among cases than among controls (P = 0.01). We observed a tendency for slightly lower PLP concentrations in cases than in controls (P = 0.08) and a tendency for slightly higher HK:XA in cases than in controls (P = 0.06). PAr was higher in cases than in controls (P = 0.03). The associations between potential confounders and the biomarkers are shown in Supplemental Table 1 and Supplemental Figure 2. Overall, the effect size of the associations was weak, with the possible exception of lower PLP for ex-smokers and for participants with a BMI ≥30 and lower alcohol or dietary fiber intake. The vitamin B-6 biomarkers did not vary by storage time (Supplemental Figure 3).

ORs for CRC risk for the quartiles of PLP, HK:XA, and PAr are presented in Figure 1. The association between PLP and CRC risk was strongest for the third compared with the first (lowest) quartile [OR: 0.60 (95% CI: 0.44, 0.81), Pr = 0.07; OR per 1-SD increase: 0.94 (95% CI: 0.83, 1.05)]. PLP sufficiency was associated with a lower risk of CRC compared with deficiency [OR: 0.55 (95% CI: 0.37, 0.81); risk difference: 476 fewer cases/100,000 individuals (95% CI: 859, 17)]. Higher HK:XA was associated with increased CRC risk for the fourth compared with the first quartile [OR: 1.48 (95% CI: 1.08, 2.02), Pr = 0.02; OR per 1-SD increase: 1.14 (95% CI: 1.02, 1.28)]. The association for PAr was similar for the fourth compared with first quartile [OR: 1.50 (95% CI: 1.10, 2.04), Pr = 0.01; OR per 1-SD increase: 1.18 (95% CI: 1.05, 1.31)]. The corresponding absolute risk differences were a decrease in incidence of 325 cases/100,000 individuals for the third compared with the first quartile of PLP (decrease of 45 cases/100,000 individuals per 1-SD increase) and an increase of 211 and 273 cases/100,000 individuals for the fourth compared with the first quartiles of HK:XA and PAr (increase of 68 and 131 cases/100,000 individuals per 1-SD increase), respectively. The inclusions of potential confounders did not markedly alter any risk estimates.

To adjust for potential confounders, several variables with a plausible link to both exposure and outcome were considered. These included the plasma B vitamins folate, riboflavin, and vitamin B-12 (continuous, log-transformed); estimated glomerular filtration rate calculated by the Cockcroft-Gault formula (based on plasma creatinine concentrations, age, sex, and body weight) (35); smoking status; BMI (in kg/m²); alcohol intake; dietary fiber intake; and recreational and occupational physical activity. In the conditional logistic regression models, 3 models were estimated for each vitamin B-6 marker. Model 1 represented an unadjusted model. Model 2 was adjusted for estimated glomerular filtration, smoking status, BMI, alcohol intake, and recreational and occupational physical activity. Model 3 was additionally adjusted for the plasma B vitamins folate, riboflavin (vitamin B-2), and cobalamin (vitamin B-12). For the risk differences, a crude estimate adjusted only for the matching (vitamin B-6 status), were both associated with an increased CRC risk for the fourth compared with the first quartile of PLP (decrease of 45 cases/100,000 individuals per 1-SD increase) and an increase of 211 and 273 cases/100,000 individuals for the fourth compared with the first quartiles of HK:XA and PAr (increase of 68 and 131 cases/100,000 individuals per 1-SD increase), respectively. The inclusions of potential confounders did not markedly alter any risk estimates.

Dose-response relations of the vitamin B-6-markers in relation to CRC risk modeled with restricted cubic splines are presented in Figure 2. Although linearity could not be rejected for any marker in the spline regressions, the association for PLP had nonlinear tendencies manifested as a U-shaped association with a particularly high risk for low concentrations (Pr_nonlinearity = 0.05).

In Figure 3, we present ORs according to follow-up time between sampling and CRC diagnosis. The association for PLP seemed to be similar across follow-up times. Pr_trend was significantly linearly associated with CRC risk for HK:XA and PAr in the subgroups with <10.5 y of follow-up but not for the HK:XA and PAr subgroups with ≥10.5 y of follow-up. Similarly, a per 1-SD increase was significantly associated with increased CRC risk in the HK:XA and PAr subgroups with <10.5 y of follow-up but not in the subgroups with ≥10.5 y of follow-up. However, overall heterogeneity for the associations between all follow-up groups was only significant for HK:XA (Pr_heterogeneity = 0.02). We observed no clear differences in associations between site, stage, sex, or age, and no overall tests of heterogeneity were significant (Supplemental Tables 2–4). However, a 1-SD increase of PAr was significantly associated with left-sided CRC (Supplemental Table 2).

DISCUSSION

In this prospective study, the risk of CRC was highest in participants with the lowest plasma PLP concentrations. High HK:XA, indicating low functional vitamin B-6 status, and PAr, a marker of inflammatory and oxidative stress as well as low vitamin B-6 status, were both associated with an increased CRC risk. For both HK:XA and PAr, the associations were mainly

VITAMIN B-6 MARKERS AND COLORECTAL CANCER RISK 899

The American Journal of Clinical Nutrition
observed in participants with follow-up times of <10.5 y between sampling and CRC diagnosis.

Although the relation between plasma PLP concentrations and CRC risk was nonlinear in our study, the highest risk was consistently observed in participants with the lowest PLP, assessed as the lowest quartile, as concentrations under the clinically relevant cutoff for deficiency (20 nmol/L), and in the regression spline models. Our results are thus in line with previous

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Baseline characteristics of colorectal cancer cases and their matched controls and the tumor characteristics of cases1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases</td>
</tr>
<tr>
<td></td>
<td>n</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>253</td>
</tr>
<tr>
<td>Women</td>
<td>360</td>
</tr>
<tr>
<td>Age at sampling, y</td>
<td>613</td>
</tr>
<tr>
<td>Follow-up time, y</td>
<td>613</td>
</tr>
<tr>
<td>eGFR, mL $\cdot$ min $^{-1} \cdot 1.73$ m$^{-2}$</td>
<td>596</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>114</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>136</td>
</tr>
<tr>
<td>Never</td>
<td>361</td>
</tr>
<tr>
<td>BMI, kg/m$^2$</td>
<td>591</td>
</tr>
<tr>
<td>Alcohol intake,4 g/d</td>
<td>385</td>
</tr>
<tr>
<td>Dietary fiber intake,5 g/2000 kcal</td>
<td>359</td>
</tr>
<tr>
<td>Recreational physical activity4,6 1</td>
<td>221</td>
</tr>
<tr>
<td>2</td>
<td>117</td>
</tr>
<tr>
<td>3</td>
<td>81</td>
</tr>
<tr>
<td>4</td>
<td>29</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td>Occupational physical activity4,7 1</td>
<td>90</td>
</tr>
<tr>
<td>2</td>
<td>77</td>
</tr>
<tr>
<td>3</td>
<td>111</td>
</tr>
<tr>
<td>4</td>
<td>102</td>
</tr>
<tr>
<td>5</td>
<td>36</td>
</tr>
<tr>
<td>Tumor site8</td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>183</td>
</tr>
<tr>
<td>Left colon</td>
<td>215</td>
</tr>
<tr>
<td>Rectum</td>
<td>214</td>
</tr>
<tr>
<td>Stage9</td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>308</td>
</tr>
<tr>
<td>III–IV</td>
<td>276</td>
</tr>
<tr>
<td>Plasma concentrations</td>
<td></td>
</tr>
<tr>
<td>PLP, nmol/L</td>
<td>608</td>
</tr>
<tr>
<td>Pyridoxal, nmol/L</td>
<td>606</td>
</tr>
<tr>
<td>PA, nmol/L</td>
<td>608</td>
</tr>
<tr>
<td>PAr, nmol/L</td>
<td>606</td>
</tr>
<tr>
<td>3-hydroxykynurenine, nmol/L</td>
<td>606</td>
</tr>
<tr>
<td>XA, nmol/L</td>
<td>608</td>
</tr>
<tr>
<td>HK:XA</td>
<td>606</td>
</tr>
<tr>
<td>Folate, nmol/L</td>
<td>613</td>
</tr>
<tr>
<td>Vitamin B-2, nmol/L</td>
<td>608</td>
</tr>
<tr>
<td>Vitamin B-12, nmol/L</td>
<td>603</td>
</tr>
</tbody>
</table>

1 eGFR, estimated glomerular filtration rate; HK:XA, 3-hydroxykynurenine:xanthurenic acid ratio; PA, pyridoxic acid; PAr, pyridoxic acid;(PLP + pyridoxal); PLP, pyridoxal 5’-phosphate; VIP, V¨asterbotten Intervention Program; XA, xanthurenic acid.
2 Test for difference in distribution between cases and controls. Mann-Whitney U tests were used for continuous variables and chi-square tests were used for categorical variables.
3 Values are percentages or medians (5th–95th percentiles).
4 Variables were available only for the VIP cohort.
5 Estimated from self-administered semiquantitative food-frequency questionnaires designed to measure intakes from the previous year in mass per day divided by total energy intake.
6 Self-reported on a scale from 1 to 5 ranging from no exercise during leisure time to exercise >3 times/wk.
7 Self-reported on a scale from 1 to 5 ranging from low to high physical effort at work.
8 Could not be determined for 1 case.
9 Could not be determined for 29 cases.
findings (1, 3–7). In our study, PLP status above sufficiency was not associated with any additional lowering of CRC risk. Plasma PLP is influenced by dietary vitamin B-6 intake and supplementation, plasma albumin and alkaline phosphatase concentrations, kidney function, smoking, and alcohol intake (21, 37), which may contribute to PLP variability (22). PAr is less prone to confounding by a high vitamin B-6 intake (22), which may explain the linear association between PAr and CRC risk. Our results for PAr are in accordance with a previous cohort study that included 158 CRC cases (23). To our knowledge, HK:XA has not previously been studied in relation to CRC risk. The positive association between HK:XA and CRC risk in this study was apparent primarily in the fourth quartile, suggesting that metabolic alterations in the kyurenine pathway may contribute to the increased CRC risk at low PLP concentrations. HK:XA seems to be a valuable complement to PLP in investigations of vitamin B-6 and disease risk.
Inflammatory activity is causally related to cancer development (38), particularly for CRC, for which inflammatory bowel disease is an established risk factor (18). Many environmental CRC risk factors, such as smoking, infections, obesity and diet, are associated with inflammatory activity (38). Inflammation may therefore be a common underlying carcinogenic mechanism for several risk factors that together contribute to the association between inflammatory markers, including PAr, and CRC risk. For PAr, an inverse marker of vitamin B-6 status, confounding by these risk factors may also be present, but adjusting the multivariable analyses had essentially no effect on the results. PAr was mainly associated with CRC risk in the subgroup with 10.5 y from baseline to CRC diagnosis. Given the slow progression of colorectal lesions, this finding is consistent with previous findings for the inflammatory marker CRP of a direct association with the risk of CRC but not colorectal adenoma (10, 14, 15, 39). Because undiagnosed cancerous lesions at baseline were unlikely to be present in the group with ≥10.5 y of follow-up, the putative role in CRC may occur once a lesion has been established (i.e., tumor progression) and not in the healthy mucosa (i.e., tumor initiation). However, for PLP, the risk relation was similar across follow-up groups, possibly reflecting the complexity in determinants of PLP status. Although our results did not differ significantly by tumor site, the association between PAr and CRC risk was strongest in cases with left-sided colon cancer, which is in line with several studies on different inflammatory biomarkers and CRC (14, 16, 40).

Cancer, including CRC, is known to reduce plasma concentrations of PLP (21). The underlying mechanisms may include increased catabolism and tissue redistribution (19, 22). Furthermore, vitamin B-6 concentrations are >2-fold higher in colorectal tumors than in normal mucosa (41), which might be caused by inflammation-related tissue redistribution or elevated metabolic demands of the growing tumor. Given the slow development of CRC, observed risk relations may therefore reflect an influence of undiagnosed disease at baseline on circulating markers (reverse causation). However, the opposite is also possible; i.e., vitamin B-6 and inflammation may influence the progression of established but undiagnosed CRC (10, 42). Although the study design did not allow us to distinguish between these 2 relations, in our subgroup analyses for PAr and HK:XA, participants with 5.8 y from sampling to CRC diagnosis (likely to have the greatest tumor burden) did not have a statistically stronger association to CRC risk than those with 5.8–10.5 y from baseline to diagnosis.

The main strength of our study was the use of 3 vitamin B-6 markers to allow a more comprehensive assessment of vitamin B-6 status and, to some extent, account for the many determinants of PLP variability. Other important strengths of our study include the population-based prospective design, large sample size, and long follow-up. A large proportion of the samples were collected after ≥8 h of fasting, and the sample handling procedures and laboratory analyses were of very high quality. We also present both relative and absolute risk estimates, which is of value in interpreting the clinical relevance of the results. We analyzed a single baseline blood sample per participant, which may not be representative of vitamin B-6 status over time and could result in...
an underestimation of the true risk relations caused by re-
gression dilution (43). We adjusted for several potentially im-
portant parameters, including kidney function, one-carbon meto-
labolites, and several established risk factors for CRC. We
were not able to control for several potential confounders, such
as nonsteroidal anti-inflammatory drug use and hereditary CRC,
but the use of biomarkers of functional vitamin B-6 status, in-
cluding the inflammatory marker PAr, may have reduced the risk
of confounding from inflammation. We were also not able to
control for CRC screening because there was no formal CRC
screening program in the source population, and opportunistic
screening was found to be essentially nonexistent in a similar
Swedish cohort (44).

In conclusion, in this nested case-control study, vitamin B-6
sufficiency compared with deficiency defined by PLP concen-
trations was associated with a clear decrease in CRC risk. The
association was consistent with a role in tumor progression rather
than initiation.

We thank Åsa Ågren at the Department of Biobank Research for excellent
assistance.

The authors’ responsibilities were as follows—BG, GH, IJ, PMU, BVG,
and RP: designed the research; BG, RM, JS, JH, BVG, and RP: planned
and/or conducted the data analysis; BG, RM, AU, and BVG: wrote
the manuscript; JS, GH, JH, DJ, PMU, and RP: critically revised the manuscript
for important intellectual content; RP: had primary responsibility for the
final content; and all authors: read and approved the final manuscript. None
of the authors reported a conflict of interest related to the study.

REFERENCES

1. Zhang XH, Ma J, Smith-Warner SA, Lee JE, Giovannucci E. Vitamin
B6 and colorectal cancer: current evidence and future directions. World
Meyerhardt J, Giovannucci E. Prediagnostic plasma vitamin B6 (pyr-
cinolase 5'-phosphate) and survival in patients with colorectal cancer.
3. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal
cancer: a meta-analysis of prospective studies. JAMA 2010;303:
1077–83.
4. Le Marchand L, White KK, Nomura AM, Wilkens LR, Selhub J,
Türikainen M, Goodman MT, Murphy SP, Henderson BE, Kolonel LN.
Plasma levels of B vitamins and colorectal cancer risk: the multiethnic
5. Lee JE, Li H, Giovannucci E, Lee IM, Selhub J, Stampfer M, Ma J.
Prospective study of plasma vitamin B6 and risk of colorectal cancer in
6. Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma J.
Plasma vitamin B6 and the risk of colorectal cancer and adenoma in
7. Weinstein SJ, Albanes D, Selhub J, Graubard BI, Lim U, Taylor PR,
Virtamo J, Stolzenberg-Solomon R. One-carbon metabolism bio-
markers and risk of colon and rectal cancers. Cancer Epidemiol Bio-
Cancer incidence and mortality after treatment with folic acid and
9. Paul L, Ueland PM, Selhub J. Mechanistic perspective on the re-
relationship between pyridoxal 5'-phosphate and inflammation. Nutr Rev
2013;71:239–44.
review of the application of inflammatory biomarkers in epidemi-
ologic cancer research. Cancer Epidemiol Biomarkers Prev 2014;23:
1729–51.
Inflammation-induced cancer: crosstalk between tumours, immune cells
12. Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J. Vitamin
B-6 intake is inversely related to, and the requirement is affected by,
13. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circu-
lating vitamin B(6) is associated with elevation of the inflammation
marker C-reactive protein independent of plasma homocysteine levels.
14. Aleksandrova K, Janeb M, Boehting H, Jansen E, Bueno-de-Mesquita HB,
C-reactive protein concentrations and risks of colon and rectal cancer:
a nested case-control study within the European Prospective Investigation
15. Tsilidis KK, Branchini C, Guilara E, Helzlsouer KJ, Erlinger TP,
Platz EA. C-reactive protein and colorectal cancer risk: a systematic
Miller JW, Song X, Beresford SA, Gunter MJ, et al. Biomarkers of
inflammation are associated with colorectal cancer risk in women but
are not suitable as early detection markers. Int J Cancer 2013;132:
2648–58.
Meucci G, Spina L, de Francisis R. Low vitamin B(6) plasma levels, a
risk factor for thrombosis, in inflammatory bowel disease: role of in-
flammation and correlation with acute phase reactants. Am J Gastro-
18. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated
19. Midttun O, Ulvik A, Riedel-Pedersen EE, Ebbing M, Bleie O,
Schartum-Hansen H, Nilsen RM, Nygard O, Ueland PM. Low plasma
vitamin B-6 status affects metabolism through the kyurenine path-
way in cardiovascular patients with systemic inflammation. J Nutr
2011;141:611–7.
20. Ulvik A, Theolylaktopoulou D, Midttun O, Nygard O, Eussen SJ,
Ueland PM. Substrate product ratios of enzymes in the kyurenine
pathway measured in plasma as indicators of functional vitamin B-6
21. Ulvik PM, Ulvik A, Rios-Avila L, Midttun O, Gregory JF. Direct and
functional biomarkers of vitamin B6 status. Annu Rev Nutr 2015;35:
33–70.
Evidence for increased catalysis of vitamin B-6 during systemic
23. Zuo H, Ueland PM, Eussen SJ, Tell GS, Vollset SE, Nygard O,
Midttun O, Meyer K, Ulvik A. Markers of vitamin B6 status and
metabolism as predictors of incident cancer: the Hordaland Health
folic and total homocysteine levels are associated with the risk of
myocardial infarction, independently of each other and of renal func-
25. Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V,
Pihl E, Karpe H, Laippala P, Jousilahti P, et al. The association of
folic acid and plasma total homocysteine levels is related to the risk
in plasma vitamin B6 and colorectal cancer: a nested case-control study
within the European Prospective Investigation into Cancer and Nutrition.